Cargando…

Trends in COVID-19-associated mortality in patients with pulmonary hypertension: a COMPERA analysis

In patients with pulmonary hypertension, the mortality rate associated with COVID-19 has declined sharply with the emergence of the Omicron variants https://bit.ly/42OMsfj

Detalles Bibliográficos
Autores principales:	Schmidt, Kai-Helge, Milger, Katrin, Pausch, Christine, Huscher, Doerte, Pittrow, David, Grünig, Ekkehard, Staehler, Gerd, Gall, Henning, Distler, Oliver, Skowasch, Dirk, Halank, Michael, Wilkens, Heinrike, Held, Matthias, Klose, Hans, Hoeper, Marius M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2023
Materias:	Research Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133582/ https://www.ncbi.nlm.nih.gov/pubmed/37105586 http://dx.doi.org/10.1183/13993003.02440-2022

Ejemplares similares

Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry
por: Hoeper, Marius M., et al.
Publicado: (2022)

COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension
por: Hoeper, Marius M., et al.
Publicado: (2022)

Performance of the ESC/ERS 4-strata risk stratification model for pulmonary arterial hypertension with missing variables
por: Pausch, Christine, et al.
Publicado: (2023)

Pulmonary Hypertension in Adults with Congenital Heart Disease: Real-World Data from the International COMPERA-CHD Registry
por: Kaemmerer, Harald, et al.
Publicado: (2020)

Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis
por: Hoeper, Marius M, et al.
Publicado: (2022)

Pulmonary Hypertension in Patients with Chronic Fibrosing Idiopathic Interstitial Pneumonias
por: Hoeper, Marius M., et al.
Publicado: (2015)

Incidence and characteristics of chronic thromboembolic pulmonary hypertension in Germany
por: Kramm, Thorsten, et al.
Publicado: (2018)

Long-term effects of intravenous iloprost in patients with idiopathic pulmonary arterial hypertension deteriorating on non-parenteral therapy
por: Knudsen, Lars, et al.
Publicado: (2011)

Exercise training improves peak oxygen consumption and haemodynamics in patients with severe pulmonary arterial hypertension and inoperable chronic thrombo-embolic pulmonary hypertension: a prospective, randomized, controlled trial
por: Ehlken, Nicola, et al.
Publicado: (2016)

Gene panel diagnostics reveals new pathogenic variants in pulmonary arterial hypertension
por: Eichstaedt, Christina A., et al.
Publicado: (2022)

Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)
por: Marra, Alberto M., et al.
Publicado: (2018)

Profiles and treatment patterns of patients with pulmonary arterial hypertension on monotherapy at experienced centres
por: Wissmüller, Max, et al.
Publicado: (2022)

Anticoagulation in pulmonary arterial hypertension: Contemporary data from COMPERA registry
por: Said, Karim
Publicado: (2014)

Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH
por: Gall, Henning, et al.
Publicado: (2018)

Exercise training in pulmonary arterial hypertension associated with connective tissue diseases
por: Grünig, Ekkehard, et al.
Publicado: (2012)

Myeloproliferative Diseases as Possible Risk Factor for Development of Chronic Thromboembolic Pulmonary Hypertension—A Genetic Study
por: Eichstaedt, Christina A., et al.
Publicado: (2020)

Reduction of BMPR2 mRNA Expression in Peripheral Blood of Pulmonary Arterial Hypertension Patients: A Marker for Disease Severity?
por: Theobald, Vivienne, et al.
Publicado: (2022)

Practical management of riociguat in patients with pulmonary arterial hypertension
por: Halank, Michael, et al.
Publicado: (2019)

Late outcomes after acute pulmonary embolism: rationale and design of FOCUS, a prospective observational multicenter cohort study
por: Konstantinides, Stavros V., et al.
Publicado: (2016)

Mutually reinforcing effects of genetic variants and interferon-β 1a therapy for pulmonary arterial hypertension development in multiple sclerosis patients
por: Lerche, Marianne, et al.
Publicado: (2019)

Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism: the FOCUS study( )
por: Valerio, Luca, et al.
Publicado: (2022)

Is iron deficiency caused by BMPR2 mutations or dysfunction in pulmonary arterial hypertension patients?
por: Theobald, Vivienne, et al.
Publicado: (2023)

The original and two new derivative versions of the COMPERA 2.0 risk assessment model: useful tools for guiding balloon pulmonary angioplasty
por: Zhang, Yi, et al.
Publicado: (2022)

Impact of SARS-CoV-2 pandemic on pulmonary hypertension out-patient clinics in Germany: a multi-centre study
por: Yogeswaran, Athiththan, et al.
Publicado: (2020)

Efficacy and safety of nasal high-flow oxygen in COPD patients
por: Vogelsinger, Helene, et al.
Publicado: (2017)

Anxiety and depression disorders in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Harzheim, Dominik, et al.
Publicado: (2013)

Kriterien zur Evaluation des Ansprechens auf Biologika bei schwerem Asthma – der Biologics Asthma Response Score (BARS)
por: Milger, Katrin, et al.
Publicado: (2023)

Real-World Experience on the Use of Mepolizumab from the Severe Asthma Registry of the German Asthma Net (MepoGAN-Study)
por: Korn, Stephanie, et al.
Publicado: (2023)

Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed
por: Denton, Christopher P, et al.
Publicado: (2011)

Investigating significant health trends in idiopathic pulmonary fibrosis (INSIGHTS-IPF): rationale, aims and design of a nationwide prospective registry
por: Behr, Juergen, et al.
Publicado: (2014)

Riociguat dose titration in patients with chronic thromboembolic pulmonary hypertension (CTEPH) or pulmonary arterial hypertension (PAH)
por: Ghofrani, Hossein A, et al.
Publicado: (2009)

Prevalence of Patients with Uncontrolled Asthma Despite NVL/GINA Step 4/5 Treatment in Germany
por: Bergmann, Karl-Christian, et al.
Publicado: (2022)

Health Care Situation in the Treatment of Uncontrolled GINA Step 4/5 Patients in Germany
por: Timmermann, Hartmut, et al.
Publicado: (2023)

Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry
por: Behr, Jürgen, et al.
Publicado: (2015)

Survival with sildenafil and inhaled iloprost in a cohort with pulmonary hypertension: an observational study
por: Gall, Henning, et al.
Publicado: (2016)

Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients
por: Schmidt, Katrin, et al.
Publicado: (2009)

Investigating significant health trends in growth hormone treatments registry: rationale, aims and design of a nationwide prospective registry (study protocol)
por: Schnabel, Dirk, et al.
Publicado: (2023)

Flow rate variance of a fully implantable pump for the delivery of intravenous treprostinil in pulmonary arterial hypertension
por: Richter, Manuel J., et al.
Publicado: (2020)

Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study
por: Brueckner, Claudia S, et al.
Publicado: (2010)

An epidemiological analysis of the burden of chronic thromboembolic pulmonary hypertension in the USA, Europe and Japan
por: Gall, Henning, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ugu7e2csgqt4ab3pcv7tqk7hbl